Mapping Global Scientific Production on Human Immunodeficiency Virus and Monkeypox: A Scientometric Study

Area of Science:

• Public Health
• Virology
• Epidemiology

Background:

• Human Immunodeficiency Virus (HIV) compromises the immune system, potentially leading to Acquired Immunodeficiency Syndrome (AIDS).
• Monkeypox (MPVX), a zoonotic disease, presents a lesser threat than smallpox but carries increased risks for immunocompromised individuals, particularly those with HIV.
• Effective prevention and treatment strategies for both MPVX and HIV are essential public health priorities.

Purpose of the Study:

• To conduct a bibliometric analysis of global academic research output on Monkeypox (MPVX) and Human Immunodeficiency Virus (HIV) between 2018 and 2023.
• To assess research productivity, identify key publication sources, and analyze collaboration patterns in MPVX and HIV research.

Main Methods:

• A descriptive bibliometric study was performed, systematically searching for literature on "monkeypox" and "HIV" published from 2018 to 2023.
• Data from 366 identified articles were analyzed using SciVal and Bibliometrix in R Studio to evaluate research trends, collaborations, and citation impact.
• Metadata analysis included publication sources, institutional contributions, and keyword frequencies.

Main Results:

• A total of 366 papers on MPVX and HIV were published across 183 sources between 2018-2023, demonstrating a substantial annual growth rate of 208.18%.
• The average citation count per paper was 14.78, indicating significant impact and interest in the research.
• "Journal of Medical Virology" and "The Lancet Infectious Diseases" were leading publication venues, while France's "Institut national de la santé et de la recherche médicale" showed the highest institutional output.

Conclusions:

• Academic research on Monkeypox and HIV has experienced significant growth and demonstrates robust international collaboration.
• The findings highlight the global importance and escalating impact of research addressing both Monkeypox and HIV co-infections and individual disease burdens.